Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
MetLife has delivered a strong 82.3% total return over the past five years, yet today the stock screens as expensive on traditional multiples while an Excess Returns intrinsic value estimate points to meaningful upside, so investors are getting mixed signals on what the current US$96.73 share price really implies.
-
Over five years, MetLife has returned 82.3%, which puts recent valuation concerns in the context of a stock that has already created substantial shareholder value over a longer window.
-
The new US$3.4b total buyback capacity may support per share value if executed as planned, although expectations baked into the price could be challenged if future cash generation does not keep pace with that capital return.
-
MetLife only passes 2 of 6 valuation checks, which suggests the broader set of metrics leans more toward the stock being on the expensive side rather than a clear bargain, despite the intrinsic value model implying it is undervalued by 43.2%.
The issue now is whether MetLife's current valuation leaves enough margin of safety once these conflicting signals are weighed together.
Is MetLife Still Cheap on Excess Returns?
The Excess Returns model looks at how much value MetLife creates above the cost of its equity capital. For MetLife, the inputs point to a company expected to earn more on its equity base than investors are requiring in return.
On the model's assumptions, book value is $43.03 per share and stable EPS is $8.49 per share, against a cost of equity of $4.06 per share. That leaves an excess return of $4.43 per share, supported by an average return on equity of 15.69% and a stable book value estimate of $54.11 per share. These estimates come from weighted future ROE and book value forecasts from 8 and 7 analysts respectively. Together they produce an intrinsic value of about $170.37 per share, which is above the current $96.73 share price and implies the stock is 43.2% undervalued. Because the board has just approved a new $3.0b share repurchase authorization, plus the remaining $0.4b under the prior plan, the modeled excess returns are being compared against an active capital return program.
On this Excess Returns view, MetLife stock appears undervalued relative to the current share price.
Our Excess Returns analysis suggests MetLife is undervalued by 43.2%. Track this in your watchlist or portfolio , or discover 50 more high quality undervalued stocks .
Has MetLife Run Too Far on Earnings?
The P/E multiple is a useful measure for MetLife because earnings are a key driver for how investors usually compare large insurers. At the current US$96.73 share price, MetLife trades on about 17.9x earnings. That is higher than the insurance industry average of roughly 11.2x and also above the peer group average of 14.9x.
The fair P/E ratio from the model is 15.9x, which is lower than where MetLife trades today. This indicates that the stock is priced at a premium to what the model suggests based on its earnings profile and risk characteristics. The gap is not extreme, but it does lean toward MetLife appearing overvalued on a straightforward earnings comparison.
On the P/E multiple, MetLife stock appears overvalued relative to both peers and the model's fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
The MetLife Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this MetLife valuation puzzle leaves off. They set out what would need to happen to growth, margins and earnings for the stock to be worth materially more or less than today's price. Each narrative links a fair value estimate to a clear story about MetLife's potential catalysts and risks, so you can see which version of events appears to be unfolding over time on the Community page.
Share a Narrative on MetLife to put your own, number driven view on the new US$3.4b repurchase capacity and whether it delivers on management's confidence. Add your voice to the Simply Wall St community and track how your thesis holds up as new results and updates come through.
Do you think there's more to the story for MetLife? Head over to our Community to see what others are saying!
The Bottom Line
MetLife's Excess Returns intrinsic value estimate flags the stock as undervalued, while the P/E based view points to an overvalued multiple relative to peers and a fair ratio. That split mainly reflects different emphases. The intrinsic view leans on how effectively MetLife can turn its equity base and capital returns into cash for shareholders, while the market multiple is more about how much growth and sentiment are already embedded in the current P/E. The key question for investors is whether MetLife can sustain the cash generation and returns implied by the intrinsic value model, or whether the current premium multiple already reflects those factors.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MET .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
